Teva Pharms Intl Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS INTL, and what generic alternatives to TEVA PHARMS INTL drugs are available?
TEVA PHARMS INTL has two approved drugs.
There is one US patent protecting TEVA PHARMS INTL drugs.
There are seventeen patent family members on TEVA PHARMS INTL drugs in twelve countries.
Summary for Teva Pharms Intl
| International Patents: | 17 |
| US Patents: | 1 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Teva Pharms Intl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-002 | Feb 1, 2007 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms Intl | SYNRIBO | omacetaxine mepesuccinate | POWDER;SUBCUTANEOUS | 203585-001 | Oct 26, 2012 | DISCN | Yes | No | 6,987,103 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharms Intl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | 7,829,121 | ⤷ Sign Up |
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-002 | Feb 1, 2007 | 8,877,245 | ⤷ Sign Up |
| Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | 7,544,372 | ⤷ Sign Up |
| Teva Pharms Intl | SYNRIBO | omacetaxine mepesuccinate | POWDER;SUBCUTANEOUS | 203585-001 | Oct 26, 2012 | 7,842,687 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARMS INTL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
| ➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
International Patents for Teva Pharms Intl Drugs
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
